CagriSema vs Amlexanox
A side-by-side research comparison of CagriSema and Amlexanox across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Amlexanox |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Amlexanox (TBK1/IKKε Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research / Off-label |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. |
| Molecular weight | Combination product | 298.29 Da |
| Half-life | 7 days (both components) | ~3-4 hours |
| Bioavailability | High (SubQ) | ~70% oral |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 25-100 mg |
| Frequency | Once weekly | 3x daily |
| Route | Subcutaneous | Oral tablet |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Related comparisons
Research and educational reference only. Not medical advice.